How do myositis and myopathy differ in definition, clinical presentation, diagnostic evaluation, and treatment?

Myositis vs Myopathy: Key Distinctions

Myositis is a specific subcategory of myopathy—myopathy is the broad umbrella term for any skeletal muscle disorder, while myositis specifically refers to inflammatory muscle disease. 1

Fundamental Definitions

Myopathy encompasses any disorder affecting skeletal muscle, regardless of cause. This includes:

• Inflammatory conditions (myositis)
• Genetic muscular dystrophies
• Metabolic disorders
• Toxic/drug-induced muscle disease
• Denervation-related muscle changes

Myositis is defined as inflammation within skeletal muscle and represents one specific category under the myopathy umbrella. 1 When occurring as part of autoimmune disease, it's termed idiopathic inflammatory myopathy (IIM). 2

Clinical Presentation Differences

Myositis (Inflammatory Myopathies)

The idiopathic inflammatory myopathies present with characteristic features that distinguish them from non-inflammatory myopathies 2:

• Onset: Subacute development over weeks to months (except IBM which is chronic) 3
• Weakness pattern: Symmetric proximal muscle weakness affecting arms and legs
• Associated symptoms: Muscle pain, fever, weight loss, and rash (particularly in dermatomyositis)
• Systemic involvement: Extramuscular manifestations including pulmonary (interstitial lung disease), cardiac, gastrointestinal, and vascular systems 2
• Laboratory findings: Clearly elevated creatine kinase (CK), often >10 times upper limit of normal in immune-mediated necrotizing myopathy 2

Specific myositis subtypes have distinct presentations 2:

• Dermatomyositis: Heliotrope rash, Gottron papules, periorbital edema, photosensitive rash with poikiloderma
• Polymyositis: CD8+ cytotoxic T cells invading nonnecrotic muscle fibers on biopsy
• Immune-mediated necrotizing myopathy: Severe myopathy with minimal inflammatory infiltrate, triggered by statins, viral infections, or malignancy
• Inclusion body myositis: Chronic progressive course with degenerative features including muscle fiber vacuolization and abnormal amyloid-β accumulation

Non-Inflammatory Myopathies (Myositis Mimics)

These conditions lack the inflammatory component but may present with similar weakness 1:

• Muscular dystrophies
• Denervation syndromes
• Diabetic myonecrosis
• Deep venous thrombosis affecting muscle
• Heterotopic ossification
• Muscle neoplasms

Diagnostic Evaluation

For Myositis (IIM)

The 2017 EULAR/ACR classification criteria provide a validated, weighted scoring system 4:

Key diagnostic elements include:

1. Myositis-specific autoantibodies: Define subgroups, predict extramuscular organ involvement (pulmonary, cardiac), and offer prognostic information 2

2. MRI findings: T1-weighted, T2-weighted sequences with fat suppression techniques and STIR identify muscle inflammation, guide biopsy site selection, and monitor treatment response 2

3. EMG abnormalities: Polyphasic motor unit action potentials of short duration and low amplitude, increased insertional activity with fibrillation potentials, sharp waves, and repetitive discharges 2

4. Muscle biopsy: Essential for definitive diagnosis, showing specific immunohistopathologic patterns for each subtype 3, 5

Classification scoring 4:

• Probability cutoff of 55% (score ≥5.5 without biopsy, ≥6.7 with biopsy) = "probable IIM"
• Sensitivity/specificity: 87%/82% without biopsies, 93%/88% with biopsies
• Sub-classification performed using a classification tree

For Non-Inflammatory Myopathies

Diagnosis requires integrated analysis distinguishing inflammatory from non-inflammatory causes 1:

• Absence of myositis-specific antibodies
• Different MRI patterns (no active muscle edema/inflammation)
• Genetic testing for muscular dystrophies
• Metabolic workup for metabolic myopathies
• Medication/toxin exposure history

Critical pitfall: IBM patients are frequently misclassified as polymyositis using older Bohan and Peter criteria, and muscular dystrophies with secondary inflammation may be misdiagnosed as myositis. 4, 3

Treatment Approaches

Myositis (IIM) Treatment

For adult patients with idiopathic inflammatory myositis, initiate high-dose corticosteroids concurrent with a steroid-sparing agent 2:

First-line regimen:

• High-dose corticosteroids PLUS
• Steroid-sparing agent: methotrexate, azathioprine, or mycophenolate mofetil
• Followed by corticosteroid taper

For juvenile dermatomyositis (uncomplicated):

• Corticosteroids 2 mg/kg up to maximum 60 mg/day with taper after 2-4 weeks
• Subcutaneous methotrexate 15 mg/m² once weekly added at treatment onset 2

For severe myositis, extensive extramuscular involvement, or refractory disease:

• High-dose methylprednisolone PLUS
• Intravenous immunoglobulin, cyclophosphamide, rituximab, or cyclosporine 2

Important exception: Inclusion body myositis is largely refractory to immunosuppressive treatment 3, 6

Non-Inflammatory Myopathies

Treatment depends entirely on the underlying cause:

• Muscular dystrophies: Supportive care, physical therapy, emerging gene therapies
• Toxic myopathies: Discontinue offending agent (e.g., statins)
• Metabolic myopathies: Specific metabolic interventions
• Denervation: Address underlying neurologic cause

The fundamental distinction is that myositis typically responds to immunosuppression, while non-inflammatory myopathies do not 3, 6. This treatment responsiveness serves as both a diagnostic and therapeutic differentiator, though definitive diagnosis should never rely solely on treatment response given the significant morbidity and mortality risks of untreated inflammatory myopathy.